Clinical Policy: (Cimzia) Reference Number: CP.PHAR.247 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description (Cimzia ) is a tumor necrosis factor (TNF) blocker. FDA Approved Indication(s) Cimzia is indicated for: Reducing signs and symptoms of Crohn s disease (CD) and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. Treatment of adults with moderately to severely active rheumatoid arthritis (RA). Treatment of adult patients with active psoriatic arthritis (PsA). Treatment of adults with active ankylosing spondylitis (AS). Policy/Criteria Provider must submit documentation (which may include office chart notes and lab results) supporting that member has met all approval criteria It is the policy of health plans affiliated with Centene Corporation that Cimzia is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Crohn s Disease (must meet all): 1. Diagnosis of CD and (a or b): a. Member is identified as moderate/high risk based on one of the following: i. Age at initial diagnosis < 30 years; ii. Extensive anatomic involvement (e.g., ileocecal disease, continuous ileocolonic disease, small bowel disease); iii. Perianal and/or severe rectal disease; iv. Deep ulcers; v. Prior surgical resection; vi. Stricturing and/or penetrating disease; b. Member has failed both of the following, unless contraindicated or clinically significant adverse effects are experienced (i and ii): i. An immunomodulator (e.g., azathioprine, mercaptopurine, methotrexate (MTX) used for 3 months; ii. Adalimumab (Humira is preferred) used for 3 consecutive months; *Prior authorization is required for adalimumab 2. Prescribed by or in consultation with a gastroenterologist; Page 1 of 8
3. Age 18 years; 4. Tuberculosis (TB) test within the past 12 months is negative, or if positive, active TB has been ruled out and the patient has received treatment for latent TB infection; 5. Dose does not exceed 400 mg subcutaneously at weeks 0, 2, and 4, followed by maintenance dose of 400 mg every 4 weeks. Approval duration: 6 months B. Rheumatoid Arthritis (must meet all): 1. Diagnosis of RA per American College of Rheumatology (ACR) criteria (refer to Appendix B); 2. Prescribed by or in consultation with a rheumatologist; 3. Age 18 years; 4. Member meets one of the following (a or b): a. Failure of MTX for 3 consecutive months unless contraindicated or clinically significant adverse effect are experienced; b. If intolerance or contraindication to MTX, failure of sulfasalazine, leflunomide, or hydroxychloroquine for 3 consecutive months unless contraindicated or clinically significant adverse effect are experienced; 5. Failure of etanercept (Enbrel is preferred) and adalimumab (Humira is preferred), each used for 3 consecutive months, unless contraindicated or clinically significant adverse effects are experienced; *Prior authorization is required for etanercept and adalimumab 6. TB test within the past 12 months is negative, or if positive, active TB has been ruled out and the patient has received treatment for latent TB infection; 7. Dose does not exceed 400 mg subcutaneously at weeks 0, 2, and 4, followed by maintenance dose of 400 mg every 4 weeks. Approval duration: 6 months C. Psoriatic Arthritis(must meet all): 1. Diagnosis of active PsA 2. Prescribed by or in consultation with a dermatologist or rheumatologist; 3. Age 18 years; 4. Member meets one of the following (a or b): a. Failure of MTX for 3 consecutive months unless contraindicated or clinically significant adverse effect are experienced; b. If intolerance or contraindication to MTX, sulfasalazine, leflunomide, or cyclosporine for 3 consecutive months unless contraindicated or clinically significant adverse effect are experienced; 5. Failure of etanercept (Enbrel is preferred) and adalimumab (Humira is preferred), each used for 3 consecutive months, unless contraindicated or clinically significant adverse effects are experienced; *Prior authorization is required for etanercept and adalimumab 6. TB test within the past 12 months is negative, or if positive, active TB has been ruled out and the patient has received treatment for latent TB infection; 7. Dose does not exceed 400 mg subcutaneously at weeks 0, 2, and 4, followed by maintenance dose of 400 mg every 4 weeks. Page 2 of 8
Approval duration: 6 months D. Ankylosing Spondylitis (must meet all): 1. Diagnosis of active AS; 2. Prescribed by or in consultation with a rheumatologist; 3. Age 18 years; 4. Failure of at least TWO non-steroidal anti-inflammatory drugs (NSAIDs) each trialed for 4 weeks unless contraindicated or clinically significant adverse effect are experienced; 5. Failure of etanercept (Enbrel is preferred) and adalimumab (Humira is preferred), each used for 3 consecutive months, unless contraindicated or clinically significant adverse effects are experienced; *Prior authorization is required for etanercept and adalimumab 6. TB test within the past 12 months is negative, or if positive, active TB has been ruled out and the patient has received treatment for latent TB infection; 7. Dose does not exceed 400 mg subcutaneously at weeks 0, 2, and 4, followed by maintenance dose of 400 mg every 4 weeks. Approval duration: 6 months E. Other diagnoses/indications 1. Refer to CP.PHAR.57 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized). II. Continued Therapy A. All Indications in Section I (must meet all): 1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria; 2. Member is responding positively to therapy (examples: sign/symptom reduction, no disease progression, no significant toxicity); 3. If request is for a dose increase, new dose does not exceed 400 mg every 4 weeks. Approval duration: 12 months B. Other diagnoses/indications (1 or 2): 1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy. Approval duration: Duration of request or 12 months (whichever is less); or 2. Refer to CP.PHAR.57 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized). III.Diagnoses/Indications for which coverage is NOT authorized: A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy CP.PHAR.57 or evidence of coverage documents. Page 3 of 8
IV. Appendices/General Information Appendix A: Abbreviation/Acronym Key ACPA: anti-citrullinated protein antibody AS: ankylosing spondylitis CRP: serum C-reactive protein DMARD: disease modifying antirheumatic drug ESR: erythrocyte sedimentation rate FDA: Food and Drug Administration MTX: methotrexate NSAID: non-steroidal anti-inflammatory drug PsA: psoriatic arthritis RA: rheumatoid arthritis TB: tuberculosis TNF: tumor necrosis factor Appendix B: The 2010 ACR Classification Criteria for RA Add score of categories A through D; a score of 6 out of 10 is needed for classification of a patient as having definite RA. A Joint involvement Score 1 large joint 0 2-10 large joints 1 1-3 small joints (with or without involvement of large joints) 2 4-10 small joints (with or without involvement of large joints) 3 > 10 joints (at least one small joint) 5 B Serology (at least one test result is needed for classification) Negative rheumatoid factor (RF) and negative anti-citrullinated protein 0 antibody (ACPA) Low positive RF or low positive ACPA. * Low: < 3 x upper limit of normal 2 High positive RF or high positive ACPA. * High: 3 x upper limit of normal 3 C Acute phase reactants (at least one test result is needed for classification) Normal C-reactive protein (CRP) and normal erythrocyte sedimentation rate 0 (ESR) Abnormal CRP or normal ESR 1 D Duration of symptoms < 6 weeks 0 6 weeks 1 Appendix C: Definition of MTX or Disease modifying antirheumatic drug (DMARD) Failure In RA, failure of MTX or DMARD is defined as < 50% decrease in swollen joint count, < 50% decrease in tender joint count, and < 50% decrease in ESR, or < 50% decrease in CRP. V. Dosage and Administration Indication Dosing Regimen Maximum Dose CD 400 mg at 0, 2, and 4 weeks, then 400 mg every 4 weeks thereafter. 400 mg every 4 weeks PsA, RA, AS 400 mg at 0, 2, and 4 weeks, then 200 mg every other week Alternative maintenance dosing: 400 mg every 4 weeks 200 mg every other week or 400 mg every 4 weeks Page 4 of 8
VI. Product Availability For Injection: 200 mg lyophilized powder for reconstitution in a single-use vial, with 1 ml of sterile water for injection Injection: 200 mg/ml solution in a single-use prefilled syringe VII. References 1. Cimzia Prescribing Information. Smyrna, GA: UCB, Inc.; January2017. Available at http://www.cimzia.com/assets/pdf/prescribing_information.pdf. Accessed August 07, 2017. 2. Lichtenstein GR, Hanauer SB, Sandborn WJ, and the Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn s disease in adults. Am J Gastroenterol. 2009; 104(2):465-483. 3. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014; 73: 492-509. 4. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012; 64(5): 625-639. 5. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6: Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011; 65(1):137-174. 6. Menter A, Gottlieb A, Feldman SR, et al. Guidelines for the management of psoriasis and psoriatic arthritis. Section 1: Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008; 58(5):826-850. 7. Ward MM, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis & Rheumatology, 2015. DOI 10.1002/ART.39298. 8. Braun J, van den berg R, et al. 2010 Update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Am Rheu Dis. 2011: 70; 896-904. 9. Sandborn WJ. Crohn s Disease Evaluation and Treatment: Clinical Decision Tool. Gastroenterology 2014; 147: 702-705. 10. Singh JA. Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care and Research. 2015; 1-25. DOI 10.1002/acr.22783 11. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative, Arthritis Rheum, 2010, vol. 62 (pg. 2569-81). Coding Implications Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to- Page 5 of 8
date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services. HCPCS Codes J0717 Description Injection, certolizumab pegol, 1 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered) Reviews, Revisions, and Approvals Date Approval Date Policy split from CP.PHAR.86.ArthritisTreatments, CP.PHAR.85 Psoriasis 6/16 08/16 Treatment, CP.PHAR.87 IBD Treatment. CD, RA, PsA, AS: Removed criteria related to HBV, malignant disease, concomitant use with other biologics, and concurrent administration of live vaccines; added dosing requirement; added requirement for trial and failure of PDL Enbrel and Humira, unless contraindicated (just Humira for CD). PsA: required trial of MTX and added requirement for the following agents as an alternative if MTX cannot be used: leflunomide, cyclosporine, sulfasalazine, azathioprine. CD: removed aminosalicylate as an option for initial therapy. RA: changed age requirement to 18 years; modified criteria to require trial of MTX, unless contraindicated; added sulfasalazine and hydroxychloroquine as an alternative to MTX if MTX is contraindicated. Re-auth: combined into All Indications; added criteria for dosing and reasons to discontinue. Modified approval duration to 6 months for initial and 12 months for renewal. Shortened background section. Converted to new template. RA: Revised criteria for confirmation of RA diagnosis per 2010 ACR Criteria. CD: revised list of poor prognostic indicators per AGA guidelines; examples of extensive disease added. Safety criteria was applied according to the safety guidance discussed at CPAC and endorsed by Centene Medical Affairs. 08/17 08/17 Important Reminder This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. Health Plan means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan s affiliates, as applicable. Page 6 of 8
The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures. This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time. This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions. Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan. This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services. Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy. 2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or Page 7 of 8
remove any trademark, copyright or other notice contained herein. Centene and Centene Corporation are registered trademarks exclusively owned by Centene Corporation. Page 8 of 8